BioRestorative Therapies Earnings Call Transcripts
Fiscal Year 2025
-
Q3 saw a sharp revenue decline due to biocosmeceutical order timing, but clinical and commercial progress accelerated, with BRTX-100 phase II enrollment nearing completion and new leadership driving biocosmeceuticals growth. Recent financing strengthened the balance sheet.
-
Q2 2025 revenue rose 240% year-over-year to $303,000, driven by BioCosmeceuticals, while net loss narrowed to $2.7 million. BRTX-100 Phase II trial enrollment surpassed halfway, showing strong safety and efficacy signals, and discussions continue for ThermoStem licensing and commercial expansion.
-
Preliminary phase two data for BRTX-100 showed over 74% of patients had significant functional improvement and pain reduction, far exceeding FDA thresholds. The therapy, using autologous stem cells, is advancing toward full enrollment and regulatory milestones.
-
Q1 2025 saw lower revenue and a higher net loss, but the cash position remains strong with no debt. Clinical progress includes FDA fast-track and IND clearance for BRTX-100, positive early trial data, and expanding IP for ThermoStem.
-
FDA cleared phase II trials for BRTX-100 in cervical discogenic pain, bypassing phase I and animal studies, and granted Fast Track for lumbar disease. The cervical trial will use a lower injection volume and is expected to be more cost-effective, with strong FDA engagement and robust market potential.
Fiscal Year 2024
-
Revenue grew 175% year-over-year with improved operating and net losses, ending 2024 with $10.7M in cash and no debt. Key milestones include FDA Fast Track for BRTX-100, IND clearance for cervical trials, and strong progress in both clinical and commercial programs.
-
Preliminary phase 2 data for BRTX-100 in CLDD show 70% of patients achieving >30% improvement in pain and function at 26 weeks, with a strong safety profile and no severe adverse events. Financially, $13.1M in cash and no debt support continued trial progress and strategic goals.